Fundraising Fox
Salarius Pharmaceuticals
NASDAQ: DCOYHouston, US · Founded 2014 · Delaware corporation · 2 known investors
Find your way into Salarius Pharmaceuticals
Sign up to see every warm intro you have to Salarius Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Salarius Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms shared across multiple viruses. Its lead programs are self-administered, nasally inhaled fusion inhibitors for respiratory viruses, including a pan-coronavirus drug for immunocompromised patients and a combined flu/COVID/RSV "tripledemic" antiviral.
Founders & leadership
Salarius Pharmaceuticals was founded in 2014 by Christoph Westphal.
CW
Christoph WestphalFounder
MR
Mark RosenblumExecutive Vice President, Chief Financial Officer
DA
David ArthurDirector and Chief Executive Officer2015–2025He is a pharmaceutical executive with experience in strategic and operational roles across drug development and commercialization, including brand management, clinical strategy, and product launches in multiple countries and therapeutic areas including diabetes and multiple sclerosis.
Board
SK
Stephen KrausBoard director
AC
Arnold C. HanishBoard director
JL
Jonathan LieberBoard director
WM
William McVicarChairman of Board
BM
Bruce McCreedyBoard director
PL
Paul LammersBoard director
TB
Tess BurlesonBoard director
PB
Peter Barton HuttBoard director
DB
David BearssBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$25.6M disclosed across 6 of 7 rounds · 2013–2024
▶$10MofferedDec 2024 · 1 investors · BiotechnologyRule 506(b)
▶$10MofferedDec 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold C. HanishDirector
- Jonathan LieberDirector
- Mark J. RosenblumExecutive Officer
- William McVicarDirector
- Bruce J. McCreedyDirector
- Paul LammersDirector
- Tess BurlesonDirector
- David ArthurDirector, Executive Officer
- Offering amount
- $10M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedMay 2023 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedMay 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ArthurExecutive Officer, Director
- Paul LammersDirector
- Mark RosenblumExecutive Officer
- William K. McVicarDirector
- Arnold C. HanishDirector
- Bruce J. McCreedyDirector
- Tess BurlesonDirector
- Jonathan LieberDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Sales commissions
- $545K
- Placement agents
- H. C. Wainwright & Co., LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedMay 2022 · 4 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMay 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LammersDirector
- Jonathan LieberDirector
- Mark J. RosenblumExecutive Officer
- William K. McVicarDirector
- Bruce McCreedyDirector
- David J. ArthurExecutive Officer, Director
- Arnold C. HanishDirector
- Tess BurlesonDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $186.8K
- Placement agents
- Ladenburg Thalmann & Co., Inc.
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$108.3KraisedNov 2016 · 8 investors · PharmaceuticalsRule 506(b)
▶$108.3KraisedNov 2016 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sunil SharmaExecutive Officer, Director, Promoter
- David J. ArthurExecutive Officer
- Jonathan NorthrupExecutive Officer, Director, Promoter
- David BearssExecutive Officer, Director, Promoter
- Offering amount
- $108.3K
- Amount sold
- $108.3K
- First sale
- Mar 2013
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$131.5KraisedNov 2016 · 7 investors · PharmaceuticalsRule 506(b)
▶$131.5KraisedNov 2016 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sunil SharmaExecutive Officer, Director, Promoter
- Jonathan NorthrupExecutive Officer, Director, Promoter
- David BearssExecutive Officer, Director, Promoter
- David J. ArthurExecutive Officer
- Offering amount
- $131.5K
- Amount sold
- $131.5K
- First sale
- Mar 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$775KraisedApr 2016 · 3 investors · PharmaceuticalsRule 506(b)
▶$775KraisedApr 2016 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David BearssDirector, Promoter
- Sunil SharmaDirector, Promoter
- David ArthurExecutive Officer
- Jonathan NorthrupDirector, Promoter
- Offering amount
- $2.7M
- Amount sold
- $775K
- First sale
- Apr 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$16.2MraisedAug 2014 · 20 investors · BiotechnologyRule 506(b)
▶$16.2MraisedAug 2014 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- Stephen KrausDirector
- Christoph WestphalExecutive Officer, Director
- Offering amount
- $22M
- Amount sold
- $16.2M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Salarius Pharmaceuticals went on to found or lead other companies.
Related companies · 5
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Salarius Pharmaceuticals.
Frequently asked questions
- What does Salarius Pharmaceuticals do?
- Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms shared across multiple viruses. Its lead programs are self-administered, nasally inhaled fusion inhibitors for respiratory viruses, including a pan-coronavirus drug for immunocompromised patients and a combined flu/COVID/RSV "tripledemic" antiviral.
- Who founded Salarius Pharmaceuticals?
- Salarius Pharmaceuticals was founded by Christoph Westphal in 2014.
- Who are Salarius Pharmaceuticals's investors?
- Salarius Pharmaceuticals's investors include Cowtown Angels, Dellin Investments.
- How much funding has Salarius Pharmaceuticals raised?
- Salarius Pharmaceuticals has disclosed $25.6M raised across 6 of its 7 known rounds.
- Where is Salarius Pharmaceuticals headquartered?
- Salarius Pharmaceuticals is headquartered in Houston, US.